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Abstract
Background: Beta-haemolytic streptococci are important contributors to the global burden of osteoarticular
infections (OAI). Knowledge on the disease traits specific for streptococcal OAI, however, remains scarce. We wished
to explore temporal trends of OAI caused by Group A Streptococci (GAS), Group B Streptococci (GBS) and Group C
and G Streptococci (GCGS), and furthermore, to describe the associated host and pathogen characteristics.
Methods: All cases of microbiologically verified β-haemolytic streptococcal OAI in Health Region Bergen, Norway,
in the period 1999–2013 were retrospectively identified. Clinical data were extracted from medical records.
Microbial isolates were submitted to antibiotic susceptibility testing and molecular typing.
Results: A total of 24 GAS, 45 GBS and 42 GCGS acute OAI were identified. The cumulative incidence of GCGS OAI,
but not GAS or GBS OAI, increased significantly from the first to the last 5-year period (IRR 5.7, p = 0.0003), with the
annual incidence peaking at 1.9/100 000 in 2013. GAS OAI generally produced the most acute and severe clinical
presentation, whereas GBS and GCGS predominantly affected the elderly, and were significantly associated with the
presence of host risk factors of systemic and focal origin, respectively.
Conclusions: We found a significantly increasing incidence of GCGS OAI, likely related to the presence of host
susceptibility factors, including prosthetic material and pre-existing joint disease. With an increasing application of
therapeutic and diagnostic bone and joint procedures, the rising trend of OAI caused by GCGS is likely to continue.
Sustained epidemiological attentiveness to GCGS seems warranted.
Keywords: Streptococcus dysgalactiae, Streptococcus pyogenes, Streptococcus agalactiae, Osteoarticular infection,
Septic arthritis, Epidemiology
Background
Osteoarticular Infections (OAI) cause significant mor-
bidity worldwide, and the incidence is increasing [1–4].
This likely reflects both a higher burden of comorbidity
in the population, and an increased performance of
surgical bone and joint procedures [1, 2].
Streptococci are consistently second only to staphylo-
cocci as causative agents of OAI, representing approxi-
mately 15–20 % of the cases [4–6]. However, knowledge
on clinical and microbial characteristics specific for
streptococcal OAI is scarce, and mostly available from
small case series published decades ago [7]. The few
retrospective cohort studies published revealed a pre-
dominance of β-haemolytic streptococci, with group A
Streptococci (GAS) and group B streptococci (GBS)
comprising the majority [8–10]. Furthermore, species-
associated clinical features were suggested; GBS mainly
affecting the multi-morbid and elderly, and GAS produ-
cing more severe clinical manifestations. However, the
number of included cases in these studies was generally
too small to permit statistical analyses or evaluate tem-
poral trends.
Streptococcus dysgalactiae subspecies equisimilis
(SDSE), a β-haemolytic streptococcus predominantly
possessing Lancefield group C or G antigen (GCS and
GGS), has recently emerged as an important pathogen,
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increasingly associated with invasive disease [11]. We
wished to explore if this rising trend was reflected in the
rates of osteoarticular GCS and GGS-infections, and to
describe the host and pathogen characteristics of these




Health Region Bergen, Western Norway, comprises the
tertiary care hospital Haukeland University Hospital, and
the two secondary care hospitals Haraldsplass Deaconess
Hospital and Voss Hospital. The population in the
catchment area increased from 360 796 to 427 486 in-
habitants during the study period. The epidemiology of
invasive β-haemolytic streptococcal disease within this
region in the period 1999–2013 has previously been de-
scribed [11]. Cases conforming to the OAI case defin-
ition were included, and demographic and clinical
information was abstracted from medical records.
Definitions
Osteoarticular infections comprised Native Joint Infec-
tions (NJI), defined as Newman group A and B [12],
Prosthetic Joint Infection (PJI), identified and classified
according to IDSA guidelines [13], and Acute Osteomye-
litis (AOM), inferred from a radiologically verified bone-
infection in conjunction with a positive blood culture or
bone biopsy obtained though intact skin. AOM included
both peripheral and vertebral osteomyelitis. Cases with
chronic osteomyelitis (symptom duration >4 weeks) or
concurrent endocarditis, were excluded. Repeatedly posi-
tive cultures with the same organism identified within
30 days of initial isolation were considered to be from a
single episode. Relapse was defined as a clinical deterior-
ation after cessation of antibiotic treatment, of verified
β-hamolytic streptococcal or unidentified microbio-
logical aetiology, resulting in a new medical or surgical
intervention. Referrals from other hospitals and patients
with a registered permanent residence address outside
the catchment area at the time of admission were
excluded. Systemic inflammatory response syndrome
(SIRS) and Streptococcal toxic shock syndrome (STSS)
were defined as previously described [14, 15]. Sequelae
were defined as presence of arthrosis, chronic joint pain,
reduced joint motility, amputation or chronic infection
treated with suppressive antibacterial therapy.
Bacterial identification, typing and antibiotic
susceptibility
All isolates displayed large colony size (>0.5 mm in
diameter after 24 h) and a β-haemolytic reaction on 5 %
sheep blood agar. Serogroup specificity was determined
using a rapid agglutination test (Oxoid Streptococcal
Grouping Kit, Hampshire, UK). As β-haemolytic GCS and
GGS causing human infections most frequently belong to
the species SDSE, and the number of GCS was very low, a
decision was made to treat them as one group (GCGS) for
statistical purposes. Nonculturable bacteria were identified
by 16 s rDNA-PCR amplification from the sample material
and subsequent sequencing, using primers and protocol as
described previously [16]. Antimicrobial susceptibility test-
ing of the invasive isolates had been performed according
to Norwegian guidelines (http://www.unn.no/fag-og-for-
skning/arbeidsgruppen-for-antibiotikasporsmal-afa). How-
ever, routine testing for erythromycin-susceptibility and
inducible clindamycin resistance was not performed prior
to 2004. emm-typing of GAS, GCS and GGS was per-
formed as described elsewhere [17]. GBS were serotyped
by ImmuLex™ Strep-B latex-agglutination (SSI Diagnostica,
Denmark).
Statistics
Data were analysed using SPSS PASW STATISTICS
(IBM SPSS Statistics for Windows, Version 21.0.
Armonk, NY: IBM Corp). Categorical data were analysed
using Chi square test or Fisher’s exact test as appropriate.
Non-parametric data were analysed using the Mann-
Whitney U-test. For Tables 1 and 2 the p-values were ad-
justed for multiple comparisons ad modum Holm-
Bonferroni. Population-data for the catchment area was
obtained from Statistics Norway (http://www.ssb.no). Inci-
dence rates were age and sex-adjusted to the 2001
Norwegian standard population. Time trends were
evaluated by dividing the data into an early cohort
(1999–2003) and a late cohort (2009–2013), and calculat-
ing mean incidence rate ratios (IRR) and a p-value. A two-
sided p-value ≤0.05 was considered statistically significant.
Results
The 15-year survey period yielded 24 GAS, 45 GBS and
42 GCGS acute Osteoarticular Infections, representing
8, 13 and 20 % of the total count of invasive episodes,
respectively. Two patients with GCGS acute OAI de-
clined participation in the study. They are represented in
the cumulative incidence, but omitted from all further
analyses. One GBS and three SDSE were identified based
on partial sequencing of 16S rDNA gene from the four
clinical samples that were culture negative. The propor-
tions of the different subgroups of OAI are described in
Table 1.
Annual incidence and seasonal variation
The cumulative incidence of GCGS OAI increased
significantly from the first to the last 5-year period
(IRR 5.7, p = 0.0003), with annual incidence peaking
at 1.9/100 000 in 2013 (Fig. 1). Conversely, the cumu-
lative incidence of GAS and GBS OAI did not display
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Table 1 Demographics, comorbidity/risk factors and disease manifestations
GAS n = 24 GBS n = 45 GCGS n = 40 a GAS vs GBS GAS vs GCGS GBS vs GCGS
Demographics Adjusted p-values *
Male sex 15 63 % 21 47 % 25 63 % 0.62 1.0 0.95
Age Median (IQR) 48 (8–72) 70 (58–80) 69 (49–81) 0.007 0.049 1.0
Disease manifestation
AOM 5 21 % 11 24 % 4 10 % 1.0 1.0 0.6
Vertebral AOM 0 7 3
Peripheral AOM 5 4 1
PJI 5 21 % 22 49 % 15 38 % 0.148 1.0 1.0
Early PJI 2 6 2
Delayed PJI 3 6 5
Late PJI 0 10 8
NJI 14 58 % 12 27 % 21 53 % 0.049 1.0 0.11
Affected joint
Hip 4 21 % 15 44 % 9 25 %
Knee 8 42 % 8 24 % 15 42 %
Ankle 2 11 % 1 3 % 3 8 %
Shoulder 0 0 % 1 3 % 4 11 %
Other 7 37 % 6 18 % 11 31 %
Multiple joints 0 0 % 5 15 % 1 3 %
Microbiological cultures
Blood 14 58 % 25 56 % 13 33 %
Synovial Fluid 14 58 % 11 24 % 23 58 %
Tissue 1 4 % 12 27 % 8 20 %
Polymicrobial b 3 13 % 2 4 % 4 10 %
Comorbidity and risk factors
Systemic risk factor 10 42 % 37 82 % 23 58 % 0.005 1.0 0.1
Diabetes 3 13 % 10 22 % 5 13 %
Chr. Org. failure 6 25 % 29 64 % 15 38 %
Active malignancy 1 4 % 8 18 % 5 13 %
Immunosuppress 1 4 % 2 4 % 4 10 %
IVDU 2 8 % 0 0 % 5 13 %
Local risk factor 10 42 % 29 64 % 29 73 % 0.21 0.084 1.0
Rheum. joint dis. 0 0 % 4 9 % 6 15 %
Prior SA 5 21 % 5 11 % 10 25 %
Prosthesis 5 21 % 22 49 % 15 38 %
Surg proc < 4 weeks 4 17 % 9 20 % 10 25 %
Any risk factor 15 63 % 41 91 % 37 93 % 0.046 0.048 1.0
All data are presented as n (%), except Age presented as median (inner quartile range (IQR)). Significant values are highlighted in bold
Abbreviations: GAS group A streptococci, GBS group B streptococci, GCGS group C and G streptococci, AOM acute osteomyelitis, PJI prosthetic joint infection,
NJI native joint infection, Chr. Org.failure chronic organ failure (according to medical records), IVDU active intravenous drug use, Rheum. Joint dis rheumatic joint
disease, SA septic arthritis, Surg proc < 4 weeks surgical joint procedure performed within 4 weeks prior to admission
* The p-values are adjusted for multiple comparisons ad modum Holm-Bonferroni
a Two GCGS cases did not provide informed consent, and were excluded from the analyses
b Three GAS, one GBS and one GCGS blood culture positive cases had concomitant Staphylococcus aureus bacteraemia. One GBS and three GCGS tissue cultures
also grew coagulase negative staphylococci
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any significant trends, and remained relatively stable
at 0.5/100 000 (IRR 1.27, p = 0.63) and 0.8/100 000
(IRR 1.77, p = 0.14), respectively.
All three groups exhibited seasonal variation, GAS
peaking in the winter with 38 % of the cases occurring
from December to February, and only 13 % during the
summer-months of June through August. Differently,
GBS and GCGS presented predominantly during sum-
mer (both 31 %), and less frequently in the winter (24
and 19 %, respectively).
Demographics and comorbidity
The demographics, risk factors and disease manifesta-
tions are shown in Table 1.
Both GBS and GCGS were significantly associated with
the presence of comorbidity and risk factors; GBS clearly
linked to systemic comorbidity, and GCGS predominantly
associated with factors of local origin. Patients presenting
with GBS or GCGS OAI were significantly older than the
GAS OAI (corrected p-value = 0.007 and p = 0.049), and a
male predominance was noted for GAS and GCGS. The
age-difference is further delineated in Fig. 2, showing that
the age-distribution for GBS and GCGS was skewed to-
wards the elderly.
Clinical characteristics, treatment and outcome
Details on clinical severity, treatment and outcome are
provided in Table 2.
Table 2 Clinical features, treatment and outcome
GAS n = 24 GBS n = 45 GCGS n = 40 a GAS vs GBS GAS vs GCGS GBS vs GCGS
Symptoms Adjusted p-values *
Duration days (IQR) 1 (1–5) 5 (2–13) 3 (1–9) 0.036 1.0 0.72
Fever 21 88 % 30 67 % 23 58 % 0.63 0.09 1.0
Severity
SIRS 18 75 % 23 51 % 24 60 % 0.48 1.0 1.0
STSS 2 8 % 0 0 % 1 3 % 0.66 1.0 1.0
Surgical treatment
NJI 14 12 21
Irrigation 8 57 % 3 25 % 13 62 %
Revision 2 14 % 2 17 % 4 19 %
Amputation 2 14 % 0 0 % 2 10 %
Antibiotics alone 2 14 % 7 58 % 2 10 %
PJI 5 22 15
Revision 5 100 % 9 41 % 7 47 %
1-stage 0 0 % 2 9 % 1 7 %
2-stage 0 0 % 5 23 % 3 20 %
Amputation 0 0 % 1 5 % 1 7 %
Antibiotics alone 0 0 % 5 23 % 3 20 %
Treatment duration
NJI days (IQR) 42 (32–52) 38 (28–76) 42 (34–56)
PJI days (IQR) 90 (14–180) 137 (76–361) 91 (42–130)
AOM days (IQR) 56 (42–56) 60 (50–116) 63 (51–81)
Outcome
Death <30 day 2 8 % 1 2 % 1 3 % 1.0 1.0 1.0
Sequelae 10 42 % 15 33 % 15 38 % 1.0 1.0 1.0
Amputation 2 8 % 2 4 % 3 8 % 1.0 1.0 1.0
Relapse 3 13 % 9 20 % 4 10 % 1.0 1.0 1.0
Chronic suppression 0 0 % 5 11 % 1 3 % 0.8 1.0 1.0
All data are presented as n (%), except “Duration of symptoms” and “Treatment duration” presented as median number of days (Inner Quartile Range
(IQR)). Significant values are highlighted in bold
Abbreviations: GAS group A streptococci, GBS group B streptococci, GCGS group C and G streptococci, SIRS systemic inflammatory response syndrome,
STSS streptococcal toxic shock syndrome, NJI native joint infection, PJI prosthetic joint infection, AOM acute osteomyelitis
* The p-values are adjusted for multiple comparisons ad modum Holm-Bonferroni
a Two GCGS cases did not provide informed consent, and were excluded from the analyses
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OAI caused by GAS generally presented more acutely,
and were frequently admitted to hospital within 1 day of
disease onset. Furthermore, they were associated with in-
creased severity and a worse outcome as compared to OAI
caused by GBS and GCGS, although the finding did not
reach clinical significance. Bacteraemia was present in 58,
56 and 33 % of GAS, GBS and GCGS-cases, respectively.
Most patients were treated with a combination of sur-
gery and antibiotics. Penicillin was prescribed in 90 % of
the cases, whereas the rest were treated predominantly
with Clindamycin or Cephalosporins. Between 10–20 %
experienced recurring infections, the majority from re-
lapse within 3 months after terminating antibiotic treat-
ment. GBS was the pathogen most frequently implicated,
and five patients with GBS OAI were eventually assigned
to chronic suppressive antibiotic therapy. Recurrence was
neither associated with antibiotic resistance patterns nor
with specific emm/capsule-types. Although the overall
mortality remained low, the morbidity was substantial.
The proportion suffering from chronic sequelae ranged
















































Fig. 2 Age group related cumulative incidence of osteoarticular infections caused by GAS, GBS and GCGS
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Molecular characteristics and antimicrobial susceptibility
Altogether, 21 GAS, 30 GBS and 29 GCGS isolates were
available for typing, revealing a diverse microbial popula-
tion (Fig. 3). The major GAS emm-types were emm1 and
emm3, and stG485 dominated among GCGS, although
neither a clonal outbreak nor a temporal trend could be
inferred. Among GBS, capsule-type III and V were most
frequently identified.
All isolates were sensitive to penicillin. Resistance
to erythromycin was detected in 9/41 (22 %) of GBS
and 4/37 (11 %) of GCGS, and resistance to clinda-
mycin in 7/41 (17 %) of GBS but in none of the GCGS.
GAS were uniformly susceptible to erythromycin and
clindamycin.
Discussion
Beta-haemolytic streptococci are an important cause of
Osteoarticular infections (OAI), but their temporal
trends have previously not been explored in detail. We
found a highly significant increase in the GCGS OAI
incidence during the 15-year survey period, the annual
incidence peaking at 1.9/100 000 in 2013. To our know-
ledge, this has not been previously reported, although it
is consistent with several epidemiological studies on in-
vasive GCGS disease in general [11, 18, 19]. Conversely,
the rates of GAS and GBS OAI remained relatively
stable at 0.5/100 000 and 0.8/100 000, respectively. This
contrasts the findings from a recent study, where a 3-
fold increase in the incidence of GBS bone-infections in
the period 1995–2012 was documented [20]. However,
that study also included chronic osteomyelitis, and 76 %
of the patients in their bone-infection cohort were
diabetics. In line with our observations, though, they re-
ported a stable incidence of 0.8/100 000 for GBS joint
infections.
The increasing GCGS OAI incidence in our material
could partly be due to increased microbial sampling or
improved diagnostic procedures. However, one would
expect this to be reflected also in the rates of GAS and
GBS OAI, but these remained stationary. The ageing
and increasingly comorbid population is probably of
importance, but surprisingly did not affect the rates of
GBS OAI, although GBS and GCGS both appear to pref-
erentially target the elderly and the vulnerable patients.
Acquisition of novel virulence factors enhancing invasive
potential or conferring specific osteoarticular tissue trop-
ism could be a contributing factor, and horizontal genetic
transfer between streptococci has been inferred [21].
Experimental arthritis studies indicate a pivotal role for
bacterial adhesins in the pathogenesis, but the knowledge
on adhesins in GCGS is limited at present [22–24].
Osteoarticular infections are one of the major disease
manifestations of GCGS, constituting approximately 20 %
of invasive disease, and further exploration of the molecu-
lar basis for their arthritogenicity is warranted [11].
We observed several species-associated clinical charac-
teristics. GAS OAI tended to present more acutely, to
produce a more severe clinical picture, and displayed the
highest propensity to cause native joint infections. GBS
and GCGS affected primarily the elderly, and were sig-
nificantly associated with the presence of comorbidity
and risk factors; GBS were clearly linked to systemic co-
morbidity, whereas GCGS were predominantly associ-
ated with local risk factors. Furthermore, GBS OAI were
frequently polyarticular, and comprised the majority of
the recurring infections. Our findings are consistent with
those from previous publications [7–10].
The antibiotic treatment was concordant with estab-
lished national guidelines regarding choice of antimicrobial
agent and length of treatment. The surgical intervention,
however, occasionally diverged from current standards
[13]. Several PJIs were treated with curative intention with
antibiotics alone, particularly in the earliest time-period.
This probably had an impact on the rates of recurring in-
fections and sequelae, although, GBS have been reported
to be associated with high relapse rates in prosthetic joint
infections compared to other pathogens [25].
Previously, emm4, emm12 and emm28 have been asso-
ciated with infective arthritis [26–28]. We found a sub-
stantial molecular diversity among our isolates, and
although these three emm-types were represented, they




















































Fig. 3 Distribution of GAS and GCGS emm-types and GBS capsule-types
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the identified emm-types for both GAS and GCGS
conform closely to the prevailing emm-types encoun-
tered in invasive disease in general during the study
period [11]. Similarly, it is tempting to speculate that
the OAI GBS serotypes likely reflects the most preva-
lent capsule types in the population, as previously
documented in Norway [29].
The present study is limited by its retrospective design,
increasing the risk of diagnostic misclassification. How-
ever, the microbe-specific emphasis of the study, along
with a review of the local microbiological records, likely
led to the inclusion of all cases of β-haemolytic strepto-
coccal infection during the study period. Such an
approach probably conforms more closely to the true
disease burden than studies based on selected isolates
submitted to National surveillance laboratories.
The total incidence and characteristics of OAI in our
health region were unfortunately not available. Hence, a
more comprehensive comparison of the clinical features
of streptococcal OAI and OAI caused by other bacteria
was not feasible.
Sepsis has recently been redefined, and the new classi-
fication should ideally have been applied to our sample
material [30]. However, the use of the former sepsis def-
inition based on SIRS-criteria permit a better compari-
son with existing literature on OAI and streptococcal
disease in general. Furthermore, the retrospective design
of the study hampered the categorization of the patients
according to the new sepsis definition based on Sequen-
tial Organ Failure Assessment score results.
Conclusions
We found a significantly increasing incidence of GCGS
Osteoarticular infections, whereas GAS and GBS OAI
did not display any temporal trends. GCGS OAI were
clearly associated with the presence of comorbidity and
risk factors, predominantly of focal origin. With an in-
creasing application of therapeutic and diagnostic bone
and joint procedures, the rising trend of OAI caused by
GCGS is likely to continue. Sustained epidemiological
attentiveness to GCGS seems warranted.
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